Rates of recurrent VTE or VTE-related death were similar between apixaban- and enoxaparin/warfarin-treated patients across
BMI categories (Pinteraction = .63)
BMI category Apixaban
n/N		 Enoxaparin/Warfarin
n/N		   RR (95% CI) P
interaction
≤25 kg/m2 16/693 16/694
 
 1.00 (0.50-1.97) .63
>25 kg/m2 to 30 kg/m2 27/985 26/1014
 
 1.07 (0.63-1.82)
>30 kg/m2 to 35 kg/m2 9/568 16/575
 
 0.57 (0.25-1.27)
>35 kg/m2 to 40 kg/m2 4/227 6/201
 
 0.57 (0.16-2.03)
>40 kg/m2 3/122 6/134
 
 0.55 (0.14-2.15)
0
0.5
1
1.5
2
2.5
Favors apixaban
Favors enoxaparin/warfarin